Table 1 Baseline characteristics of 1986 patients with breast cancer
No. (%) | No PMRT (n = 1521) | PMRT (n = 465) | p | |
|---|---|---|---|---|
Entire Cohort (N = 1986) | ||||
Treatment era | < 0.001 | |||
1/2000–12/2009 | 959 (48.3) | 807 (53.1) | 152 (32.7) | |
1/2010–12/2014 | 1027 (51.7) | 714 (46.9) | 313 (67.3) | |
Age (years) | < 0.001 | |||
≤ 40 | 349 (17.7) | 221 (14.5) | 128 (27.5) | |
> 40 | 1637 (82.3) | 1300 (85.5) | 337 (72.5) | |
Tumor location | 0.249 | |||
Inner quadrant | 439 (22.1) | 346 (22.7) | 93 (20.0) | |
Other quadrants | 1526 (76.8) | 1162 (76.4) | 364 (78.3) | |
Unknown | 21 (1.1) | 13 (0.9) | 8 (1.7) | |
Stage (AJCC 8th ed.) | < 0.001 | |||
IA | 621 (31.3) | 508 (33.4) | 113 (24.3) | |
IB- IIA | 985 (49.6) | 760 (50.0) | 225 (48.4) | |
IIB- IIIA | 380 (19.1) | 253 (16.6) | 127 (27.3) | |
No. of positive nodes | < 0.001 | |||
1 | 1023 (51.5) | 878 (57.7) | 145 (31.2) | |
2–3 | 963 (48.5) | 643 (42.3) | 320 (68.8) | |
No. of nodes dissected | 0.002 | |||
< 10 | 124 (6.2) | 80 (5.3) | 44 (9.5) | |
≥ 10 | 1862 (93.8) | 1441 (94.7) | 421 (90.5) | |
Lympho-vascular invasion | < 0.001 | |||
Yes | 279 (14.0) | 184 (12.1) | 95 (20.4) | |
No | 1704 (85.8) | 1337 (87.9) | 367 (78.9) | |
Unknown | 3 (0.2) | 0 (0) | 3 (0.7) | |
Histological grade | 0.004 | |||
I | 76 (3.8) | 69 (4.5) | 7 (1.5) | |
II | 1309 (65.9) | 1008 (66.3) | 301 (64.7) | |
III | 601 (30.3) | 444 (29.2) | 157 (33.8) | |
T stage | 0.001 | |||
T1 | 953 (48.0) | 762 (50.1) | 191 (41.1) | |
T2 | 1033 (52.0) | 759 (49.9) | 274 (58.9) | |
Estrogen receptor | < 0.001 | |||
Negative | 509 (25.6) | 358 (23.5) | 151 (32.5) | |
Positive | 1477 (74.4) | 1163 (76.5) | 314 (67.5) | |
Progesterone receptor | < 0.001 | |||
Negative | 542 (27.6) | 369 (24.3) | 173 (37.2) | |
Positive | 1444 (72.4) | 1152 (75.7) | 292 (62.8) | |
HER2 status | 0.002 | |||
Negative | 1804 (90.8) | 1410 (92.7) | 394 (84.7) | |
Positive | 182 (9.2) | 111 (7.2) | 71 (15.3) |